{"id":"W3095325704","doi":"10.1182/blood-2020-137393","title":"Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Bosutinib; Imatinib; Medicine; Myeloid leukemia; Nilotinib; Internal medicine; Imatinib mesylate; Oncology; Dasatinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003672131,0.001133172,0.001502051,0.0003111817,0.000413818,0.001088019,0.0007464564,0.001175987,0.004206344],"category_scores_gemma":[0.001769805,0.0003336577,0.001604069,0.0003411423,0.0005463642,0.001132699,0.0005228105,0.002882963,0.0007437029],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008093104,"about_ca_system_score_gemma":0.001098052,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009433199,"about_ca_topic_score_gemma":0.002838458,"domain_scores_codex":[0.9991003,0.0005179837,0.00004966607,0.00009013722,0.0001040448,0.0001377897],"domain_scores_gemma":[0.9988582,0.0002403317,0.0003351732,0.00007158389,0.00008202774,0.0004126339],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9131757,0.01059816,0.002694462,0.0008403863,0.001926342,0.00008500472,0.00009828349,0.001493995,0.004509042,0.0002508639,0.007135113,0.05719261],"study_design_scores_gemma":[0.7372077,0.2340441,0.01781271,0.0001799195,0.002081725,0.000216913,0.00005414139,0.001227536,0.001369914,0.0003289303,0.005436981,0.00003934211],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9678639,0.01365138,0.0009707112,0.001469125,0.0003612232,0.002632948,0.005692564,0.0001634234,0.007194608],"genre_scores_gemma":[0.9734904,0.005138345,0.001694361,0.002685176,0.0005856403,0.00236106,0.009488264,0.00004282314,0.004513945],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004206344,"threshold_uncertainty_score":0.01942033,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06081154179105686,"score_gpt":0.3156738313909531,"score_spread":0.2548622895998962,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}